3 ms·
> Look at the other things the government bids on. Are they getting a good deal? New Zealand has been under a lot of pressure to weaken Pharmac, the national d
by lostlogin 8y ago
> Look at the other things the government bids on. Are they getting a good deal?
New Zealand has been under a lot of pressure to weaken Pharmac, the national drug purchasing agency, as part of the TPP agreement. It hasn’t happened yet and hopefully never will. The current system is far from perfect but we pay a lot less for funded drugs here in NZ due to Pharmacs bargaining power.
- AnthonyMouse 8y ago> New Zealand has been under a lot of pressure to weaken Pharmac, the national drug purchasing agency, as part of the TPP agreement. It hasn’t happened yet and hopefully never will. The current system is far from perfect but we pay a lot less for funded drugs here in NZ due to Pharmacs bargaining power. That's not bargaining power, it's price controls. You can have price controls even without single payer. But price controls are terrible -- if the price is too high you're paying too much, if it's too low you get shortages or providers have to cut corners to hit the price target. In the pharmaceutical market this falls squarely on the side of shortages, which are then invisible because nobody is aware of the drugs that don't exist because the developer estimated that the government wouldn't allow a high enough price to recoup the R&D cost and then didn't do the R&D. It's prisoners' dilemma at the national level -- if you defect by legislating drug prices, you pay less for drugs while other countries pay the higher rate required to fund their development. Then you say "look how great defecting is, why doesn't everybody defect?" Well, yes, that's the problem. Somebody has to pay somehow. It also makes no sense to have drug patents but then regulate prices, because the whole point of the patent system is for the market to set the price of the drug at its value over the status quo during the term of the patent. If you're just going to regulate prices then you might as well instead just get rid of drug patents and replace them with X prizes. Then drugs would be much cheaper even without price controls because they would all be generics. The problem then being that then the government would have to be good at choosing what to pay prizes for, and they probably wouldn't be very efficient at it even before corruption set in.
- lostlogin 8y agoHow is it a price control when it’s free, or something like $3 for any script I’ve ever filled. I don’t see a downside for New Zealand, but acknowledge that money has to recouped somehow. I just don’t believe anyone would sell to us at below cost.
- AnthonyMouse 8y ago> How is it a price control when it’s free, or something like $3 for any script I’ve ever filled. It's not free, the provider is getting paid out of taxes. But the price they get is chosen by the government. If they choose the wrong amount to pay they may overpay (and waste money) or underpay (and there will be less research). > I just don’t believe anyone would sell to us at below cost. Products have fixed costs (R&D) and unit costs (production). Suppose the R&D costs $10M, there are 20,000 patients world-wide and the unit production cost is only $1. Then the price per patient has to be $501 to break even, $1 to cover the production and $500 to cover the R&D. If one country says they'll only pay $100 per patient, they still make a $99 margin by selling there, but that country isn't covering their share of the R&D. And if every country was doing that, they wouldn't have done the research to begin with because they wouldn't expect to recoup the R&D cost.
- lostlogin 8y agoIt seems unlikely that NZ, population 4ish million, is exploiting the drug companies. There are insurers that operate in the US alone that have a customer base that is tens of times larger than the whole New Zealand population. Why can NZ demand a better price than them? Additionally, you say that the government risks overpaying, yet we pay less than US patients pay. And why is paying a lot in a user pays system more desirable than paying little in a socialised system? Is it because paying our share is important? The drug companies are doing just fine and don’t seem to lack profits.
- AnthonyMouse 8y ago> It seems unlikely that NZ, population 4ish million, is exploiting the drug companies. The population size has nothing to do with it. If the per-patient share of the fixed costs is $500, anyone paying less than $500/patient isn't paying their share (and someone else has to pay the difference or the research doesn't happen). > There are insurers that operate in the US alone that have a customer base that is tens of times larger than the whole New Zealand population. Why can NZ demand a better price than them? Because it isn't a free market in either case. On the one side you have a patent, and on the other side you have a monopsony government regulating prices. The first situation is completely broken for insurance companies, because patients will scream bloody murder if the insurance doesn't cover a specific drug their doctor prescribed (even when there is a much cheaper one which is 90% as good), but when it's patented that means the seller can charge monopoly rents to a captive buyer. The second situation is completely broken, because it's prisoners' dilemma again. Why not pay them below the amortized fixed cost? As long as nobody else does that it'll probably be fine, and if everybody else does then you're screwed anyway, so might as well defect. Until everybody does that. The only one that works is to have the patient paying most of the money that goes to the pharmaceutical company, so they can decide whether the advantage over the prior art alternatives is worth the price they're charging. > Additionally, you say that the government risks overpaying, yet we pay less than US patients pay. The risk is of miscalculating the cost. If you're doing an honest evaluation to try to pay your share, there is a nontrivial risk of overestimating and paying too much (as well as underestimating and defunding valuable research), and doing the estimation is hard. For example, you have to account for all the promising but failed research attempts that went before the one that finally succeeded, without creating an incentive to do tons of garbage research that always fails. Of course, that's before the perverse incentive to purposely defect and pay less than your share, which in practice causes socialized systems to err on the side of paying less and defunding research. > The drug companies are doing just fine and don’t seem to lack profits. It's not about total profits. The difference is at the margin. If you spent a million dollars and discover a drug that treats heart disease, you can make a mint, because tons of people have that. But there is some other, more promising treatment that requires you to spend ten billion dollars on research -- or a number of treatments that could each pan out but not unless you try them all to figure out which one. Then you're risking more, but it may still be worth it -- if you can save a million more people for $10,000 each in research costs, that's clearly a win, but it only happens if it's possible to charge $10,000/patient for the result. The drug companies that still exist will still turn a profit, because they only do the lower cost lower reward research. The ones that can't turn a profit given the laws will cease to exist, or never exist to begin with because investors estimate the reward to be less than the risk at the outset. Refusing to pay more than e.g. $500/patient is effectively setting the value of a human life at $500.